世界のC型肝炎治療薬市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV12167)
◆英語タイトル:Global Hepatitis C Drugs Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV12167
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:95
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートはC型肝炎治療薬の世界市場について調査・分析した資料です。種類別(抗ウイルス剤、免疫調節剤、その他)の市場規模、用途別(病院、クリニック)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別C型肝炎治療薬の競争状況、市場シェア
・世界のC型肝炎治療薬市場:種類別市場規模 2015年-2020年(抗ウイルス剤、免疫調節剤、その他)
・世界のC型肝炎治療薬市場:種類別市場規模予測 2021年-2026年(抗ウイルス剤、免疫調節剤、その他)
・世界のC型肝炎治療薬市場:用途別市場規模 2015年-2020年(病院、クリニック)
・世界のC型肝炎治療薬市場:用途別市場規模予測 2021年-2026年(病院、クリニック)
・北米のC型肝炎治療薬市場分析:米国、カナダ
・ヨーロッパのC型肝炎治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのC型肝炎治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のC型肝炎治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのC型肝炎治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Gilead sciences、Abbvi、Johnson & Johnson、Merck、Glaxosmithkline、Novartis、Bristol-Myers Squibb、Roche
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc.
Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepatitis C is caused by hepatitis C virus and affects between 130–150 million people globally every year of which approximately 700 000 people die from hepatitis C-related liver diseases. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.

Market Analysis and Insights: Global Hepatitis C Drugs Market
The global Hepatitis C Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Hepatitis C Drugs Scope and Market Size
Hepatitis C Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hepatitis C Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Gilead sciences
Abbvi
Johnson & Johnson
Merck
Glaxosmithkline
Novartis
Bristol-Myers Squibb
Roche

Market segment by Type, the product can be split into
Anti-Viral
Immuno-modulators
Others
Market segment by Application, split into
Hospitals
Clinics

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hepatitis C Drugs Revenue
1.4 Market by Type
1.4.1 Global Hepatitis C Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Anti-Viral
1.4.3 Immuno-modulators
1.4.4 Others
1.5 Market by Application
1.5.1 Global Hepatitis C Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Hepatitis C Drugs Market Perspective (2015-2026)
2.2 Global Hepatitis C Drugs Growth Trends by Regions
2.2.1 Hepatitis C Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hepatitis C Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Hepatitis C Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hepatitis C Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Hepatitis C Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Hepatitis C Drugs Players by Market Size
3.1.1 Global Top Hepatitis C Drugs Players by Revenue (2015-2020)
3.1.2 Global Hepatitis C Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Hepatitis C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hepatitis C Drugs Market Concentration Ratio
3.2.1 Global Hepatitis C Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hepatitis C Drugs Revenue in 2019
3.3 Hepatitis C Drugs Key Players Head office and Area Served
3.4 Key Players Hepatitis C Drugs Product Solution and Service
3.5 Date of Enter into Hepatitis C Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Hepatitis C Drugs Historic Market Size by Type (2015-2020)
4.2 Global Hepatitis C Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Hepatitis C Drugs Market Size by Application (2015-2020)
5.2 Global Hepatitis C Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Hepatitis C Drugs Market Size (2015-2020)
6.2 Hepatitis C Drugs Key Players in North America (2019-2020)
6.3 North America Hepatitis C Drugs Market Size by Type (2015-2020)
6.4 North America Hepatitis C Drugs Market Size by Application (2015-2020)

7 Europe
7.1 Europe Hepatitis C Drugs Market Size (2015-2020)
7.2 Hepatitis C Drugs Key Players in Europe (2019-2020)
7.3 Europe Hepatitis C Drugs Market Size by Type (2015-2020)
7.4 Europe Hepatitis C Drugs Market Size by Application (2015-2020)

8 China
8.1 China Hepatitis C Drugs Market Size (2015-2020)
8.2 Hepatitis C Drugs Key Players in China (2019-2020)
8.3 China Hepatitis C Drugs Market Size by Type (2015-2020)
8.4 China Hepatitis C Drugs Market Size by Application (2015-2020)

9 Japan
9.1 Japan Hepatitis C Drugs Market Size (2015-2020)
9.2 Hepatitis C Drugs Key Players in Japan (2019-2020)
9.3 Japan Hepatitis C Drugs Market Size by Type (2015-2020)
9.4 Japan Hepatitis C Drugs Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Hepatitis C Drugs Market Size (2015-2020)
10.2 Hepatitis C Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hepatitis C Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Hepatitis C Drugs Market Size by Application (2015-2020)

11 India
11.1 India Hepatitis C Drugs Market Size (2015-2020)
11.2 Hepatitis C Drugs Key Players in India (2019-2020)
11.3 India Hepatitis C Drugs Market Size by Type (2015-2020)
11.4 India Hepatitis C Drugs Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Hepatitis C Drugs Market Size (2015-2020)
12.2 Hepatitis C Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Hepatitis C Drugs Market Size by Type (2015-2020)
12.4 Central & South America Hepatitis C Drugs Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Gilead sciences
13.1.1 Gilead sciences Company Details
13.1.2 Gilead sciences Business Overview
13.1.3 Gilead sciences Hepatitis C Drugs Introduction
13.1.4 Gilead sciences Revenue in Hepatitis C Drugs Business (2015-2020))
13.1.5 Gilead sciences Recent Development
13.2 Abbvi
13.2.1 Abbvi Company Details
13.2.2 Abbvi Business Overview
13.2.3 Abbvi Hepatitis C Drugs Introduction
13.2.4 Abbvi Revenue in Hepatitis C Drugs Business (2015-2020)
13.2.5 Abbvi Recent Development
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Details
13.3.2 Johnson & Johnson Business Overview
13.3.3 Johnson & Johnson Hepatitis C Drugs Introduction
13.3.4 Johnson & Johnson Revenue in Hepatitis C Drugs Business (2015-2020)
13.3.5 Johnson & Johnson Recent Development
13.4 Merck
13.4.1 Merck Company Details
13.4.2 Merck Business Overview
13.4.3 Merck Hepatitis C Drugs Introduction
13.4.4 Merck Revenue in Hepatitis C Drugs Business (2015-2020)
13.4.5 Merck Recent Development
13.5 Glaxosmithkline
13.5.1 Glaxosmithkline Company Details
13.5.2 Glaxosmithkline Business Overview
13.5.3 Glaxosmithkline Hepatitis C Drugs Introduction
13.5.4 Glaxosmithkline Revenue in Hepatitis C Drugs Business (2015-2020)
13.5.5 Glaxosmithkline Recent Development
13.6 Novartis
13.6.1 Novartis Company Details
13.6.2 Novartis Business Overview
13.6.3 Novartis Hepatitis C Drugs Introduction
13.6.4 Novartis Revenue in Hepatitis C Drugs Business (2015-2020)
13.6.5 Novartis Recent Development
13.7 Bristol-Myers Squibb
13.7.1 Bristol-Myers Squibb Company Details
13.7.2 Bristol-Myers Squibb Business Overview
13.7.3 Bristol-Myers Squibb Hepatitis C Drugs Introduction
13.7.4 Bristol-Myers Squibb Revenue in Hepatitis C Drugs Business (2015-2020)
13.7.5 Bristol-Myers Squibb Recent Development
13.8 Roche
13.8.1 Roche Company Details
13.8.2 Roche Business Overview
13.8.3 Roche Hepatitis C Drugs Introduction
13.8.4 Roche Revenue in Hepatitis C Drugs Business (2015-2020)
13.8.5 Roche Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Gilead sciences、Abbvi、Johnson & Johnson、Merck、Glaxosmithkline、Novartis、Bristol-Myers Squibb、Roche

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のC型肝炎治療薬市場2026:インサイト・予測(Global Hepatitis C Drugs Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。